Karyopharm Therapeutics, Inc. (KPTI)
5.82
+0.25
(+4.49%)
USD |
NASDAQ |
Apr 01, 16:00
5.774
-0.05
(-0.79%)
After-Hours: 20:00
Karyopharm Therapeutics Research and Development Expense (TTM) : 125.32M for Dec. 31, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Gilead Sciences, Inc. | 5.688B |
| Catalyst Pharmaceuticals, Inc. | 12.71M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Agios Pharmaceuticals, Inc. | 334.36M |
| Ocugen, Inc. | 37.87M |